Parkinson’s disease drug carbidopa shows anticancer effects
European Pharmaceutical Review | September 29, 2017
Research shows the Parkinson’s disease drug carbidopa displays significant anticancer effects in both human cell lines and mice when given at normal patient dosage levels. This discovery may explain the low incidence of many cancers in patients with Parkinson’s disease and could lead the way to carbidopa being repurposed as an anticancer medication.